Fluticasone Furoate vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Fluticasone Furoate · Arnuity Ellipta
Marketed by GlaxoSmithKline
NCT00603382 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.
Reported efficacy
Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)
Result source: NCT00603278
fluticasone propionate
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone Furoate | fluticasone propionate |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT04651777 | 1.9 vs 2.1vs Fluticasone PropionateNCT004526991 other result
|
| Trough FEV1, change | 0.2 vs 0.0+0.1 vs placeboNCT0115991219 other results
| 0.2 vs 0.1+0.2 vs placeboNCT0213964425 other results
|
| ACQ-5, change | —Trial running · NCT04651777 | —Not posted · NCT00158834 |
| OCS dose reduction | —Trial running · NCT04651777 | —Not posted · NCT00158834 |
Severe exacerbations, annualised rate
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone propionate
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
1 other result
- 2.6 vs 2.7 NCT00452348
Trough FEV1, change
- Fluticasone Furoate
- 0.2 vs 0.0+0.1 vs placeboNCT01159912
19 other results
- 0.4 vs 0.2 NCT01165138
- 0.2 vs 0.0 NCT01436071
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- -0.1 vs -0.1 NCT02094937
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.1 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs -0.0 NCT00603746
- 0.2 vs -0.1 NCT00603278
- 0.2 vs 0.1 NCT01563029
- -0.5 vs -0.8 NCT01128569
- 0.1 vs 0.1 NCT01563029
- 0.3 vs 0.1 NCT01563029
- fluticasone propionate
- 0.2 vs 0.1+0.2 vs placeboNCT02139644
25 other results
- 0.2 vs 0.1 NCT02139644
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- -0.1 vs -0.1 NCT02094937
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT00452348
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01563029
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone propionate
- —Not posted · NCT00158834
OCS dose reduction
- Fluticasone Furoate
- —Trial running · NCT04651777
- fluticasone propionate
- —Not posted · NCT00158834
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. Fluticasone Furoate: 16 of 16 rows · fluticasone propionate: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone Furoate Rows use multiple source trials | fluticasone propionate Rows use multiple source trials |
|---|---|---|
| ACT Control responder rate · % of participants | 99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| ACT Total absolute change · score | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Evening PEF absolute change · L/min | 31.3 vs 9.6 placebo L/min200 µg ODc,d,b,e NCT00603382 · Phase 2 show 3 more doses25.7 vs 9.6 placebo L/min100 µg OD NCT00603382 · Phase 2 30.3 vs 9.6 placebo L/min50 µg OD NCT00603382 · Phase 2 23.6 vs 9.6 placebo L/min25 µg OD NCT00603382 · Phase 2 | 13.5 vs 5.1 placebo L/min @ 12wk100 µg ODc,d,b,e NCT01563029 · Phase 2 · registry result, not featured evidence show 5 more doses11 vs 5 placebo L/min @ 12wk100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 18.5 vs 5.1 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 18.2 vs 5 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 16.3 vs 5.1 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 16.2 vs 5 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence |
| Evening PEF absolute change · L | 24.9 vs 7.6 placebo L50 µg ODf,a,b,e NCT01436110 · Phase 3 · registry result, not featured evidence 1 other source trial22.8 vs 19.5 placebo L @ 12wk50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence | 7.45 vs 3.42 placebo L @ 12wk200 mcgc,f,a,b,e NCT01576718 · Phase 2 · registry result, not featured evidence show 7 more doses7.89 vs 3.35 placebo L @ 12wk200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 6.41 vs 3.42 placebo L @ 12wk100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 6.52 vs 3.35 placebo L @ 12wk100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 3.81 vs 3.42 placebo L @ 12wk50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 4.22 vs 3.35 placebo L @ 12wk50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 10.97 vs 3.42 placebo L @ 12wk400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 11.72 vs 3.35 placebo L @ 12wk400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence |
| FEV1 absolute change · L | -0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODg,a,b,h NCT01128569 · Phase 2 · registry result, not featured evidence | 0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDg,a,b,h NCT00452699 · Phase 4 · registry result, not featured evidence |
| Morning PEF absolute change · L/min | 35.6 vs 13.6 placebo L/min200 µg ODc,d,b,e NCT00603382 · Phase 2 show 3 more doses29.5 vs 13.6 placebo L/min100 µg OD NCT00603382 · Phase 2 33.5 vs 13.6 placebo L/min50 µg OD NCT00603382 · Phase 2 27.2 vs 13.6 placebo L/min25 µg OD NCT00603382 · Phase 2 | 15.8 vs 3.3 placebo L/min @ 12wk100 µg ODc,d,b,e NCT01563029 · Phase 2 · registry result, not featured evidence show 5 more doses14.2 vs 2.7 placebo L/min @ 12wk100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 22.8 vs 3.3 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 20.6 vs 2.7 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 21.9 vs 3.3 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 23.3 vs 2.7 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence |
| Poorly-controlled Asthma Withdrawal responder rate · % of participants | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24 h Periods absolute change · percentage points | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24-h Period percent change · % of baseline | 32% (n=95) vs 21.9% (n=94) placebo200 µg ODc,i,a,b,e NCT00603382 · Phase 2 show 3 more doses40.8% (n=110) vs 21.9% (n=94) placebo100 µg OD NCT00603382 · Phase 2 34.5% (n=98) vs 21.9% (n=94) placebo50 µg OD NCT00603382 · Phase 2 29.3% (n=96) vs 21.9% (n=94) placebo25 µg OD NCT00603382 · Phase 2 | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailyi,a,b,e NCT02301975 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24 h Periods absolute change · percentage points | -1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence 1 other source trial25.1% (n=116) vs 16.8% (n=114) placebo50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence | -1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24-h Period percent change · % of baseline | 31.7% (n=95) vs 18.4% (n=94) placebo200 µg ODc,a,b,e NCT00603382 · Phase 2 show 3 more doses38.7% (n=110) vs 18.4% (n=94) placebo100 µg OD NCT00603382 · Phase 2 31.1% (n=98) vs 18.4% (n=94) placebo50 µg OD NCT00603382 · Phase 2 25.3% (n=96) vs 18.4% (n=94) placebo25 µg OD NCT00603382 · Phase 2 | 19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg ODc,a,b,e NCT01573767 · Phase 2 · registry result, not featured evidence show 2 more doses18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence |
| Well Controlled Asthma responder rate · % of participants | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 9.5%200 µg ODj NCT00603382 · Phase 2 show 41 more results10.9%100 µg OD NCT00603382 · Phase 2 9%50 µg OD NCT00603382 · Phase 2 14.4%25 µg OD NCT00603382 · Phase 2 13.9%200 µg OD NCT00603278 · Phase 2 16.2%100 µg OD NCT00603278 · Phase 2 13.1%400 µg OD NCT00603278 · Phase 2 10.7%300 µg OD NCT00603278 · Phase 2 18.2%200 µg OD NCT00603746 · Phase 2 16.7%800 µg OD NCT00603746 · Phase 2 12.1%600 µg OD NCT00603746 · Phase 2 7.9%400 µg OD NCT00603746 · Phase 2 19.3%100 µg OD NCT01159912 · Phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 12.6%200 µg OD NCT01431950 · Phase 3 16%100 µg OD NCT01431950 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 28%100 µg OD NCT01563029 · Phase 2 27.5%50 µg OD NCT01563029 · Phase 2 20.3%25 µg OD NCT01563029 · Phase 2 13.9%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 7.2%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 9.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 22.2%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 11.3%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.8%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 3.6%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | —100/25 µg QDk NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 53.1%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 37.5%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 28%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 27.5%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 20.3%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.1%200 µg ODj NCT00603382 · Phase 2 show 41 more results1.8%100 µg OD NCT00603382 · Phase 2 1%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 1%200 µg OD NCT00603278 · Phase 2 2.9%100 µg OD NCT00603278 · Phase 2 2%400 µg OD NCT00603278 · Phase 2 0%300 µg OD NCT00603278 · Phase 2 3%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 1.8%100 µg OD NCT01159912 · Phase 3 1%100/25 µg OD NCT01165138 · Phase 3 1.7%200 µg OD NCT01431950 · Phase 3 1.7%100 µg OD NCT01431950 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1.7%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 —50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy — NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.9%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0.9%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence —100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence —200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence —100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence —100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —100 µg NCT01332292 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence —200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence —100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | —100/25 µg QDk NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence —Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%200 µg ODj NCT00603382 · Phase 2 show 41 more results0.9%100 µg OD NCT00603382 · Phase 2 0%50 µg OD NCT00603382 · Phase 2 1%25 µg OD NCT00603382 · Phase 2 0%200 µg OD NCT00603278 · Phase 2 0%100 µg OD NCT00603278 · Phase 2 1%400 µg OD NCT00603278 · Phase 2 1%300 µg OD NCT00603278 · Phase 2 2%200 µg OD NCT00603746 · Phase 2 0%800 µg OD NCT00603746 · Phase 2 0.9%600 µg OD NCT00603746 · Phase 2 0%400 µg OD NCT00603746 · Phase 2 3.5%100 µg OD NCT01159912 · Phase 3 0%100/25 µg OD NCT01165138 · Phase 3 3.4%200 µg OD NCT01431950 · Phase 3 2.5%100 µg OD NCT01431950 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 0.8%100 µg OD NCT01563029 · Phase 2 0.8%50 µg OD NCT01563029 · Phase 2 0%25 µg OD NCT01563029 · Phase 2 2.5%50 mcg NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy 0% NCT02502734 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 0.3%200/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 1.2%100/25 µg OD NCT01686633 · Phase 3 · registry result, not featured evidence 0%50 µg OD NCT01436110 · Phase 3 · registry result, not featured evidence 0.8%50 µg OD NCT01436071 · Phase 3 · registry result, not featured evidence 4.1%100/25 µg NCT01086384 · Phase 3 · registry result, not featured evidence 0.5%200/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 1.5%100/25 µg OD NCT01018186 · Phase 3 · registry result, not featured evidence 0%200/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100/25 µg PM NCT01086410 · Phase 3 · registry result, not featured evidence 0%100 µg AM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg PM NCT01808339 · Phase 2 · registry result, not featured evidence 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%100 µg NCT01332292 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence 0%200 µg OD NCT00766090 · Phase 2 · registry result, not featured evidence 0%100 µg BID NCT00766090 · Phase 2 · registry result, not featured evidence | 1.4%100/25 µg QDk NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0.8%100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence 0%50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0.8%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0%400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 200 µg ODj headache 5.3% (placebo 10.6%) nasopharyngitis 3.2% (placebo 1.1%) oropharyngitis 3.2% (placebo 1.1%) NCT00603382 · Phase 2 show 40 more results100 µg OD headache 10.9% (placebo 10.6%) nasopharyngitis 3.6% (placebo 1.1%) oropharyngitis 3.6% (placebo 1.1%) NCT00603382 · Phase 2 50 µg OD headache 6% (placebo 10.6%) back pain 3% (placebo 0%) oropharyngitis 1% (placebo 1.1%) NCT00603382 · Phase 2 25 µg OD headache 6.2% (placebo 10.6%) back pain 0% (placebo 0%) nasopharyngitis 0% (placebo 1.1%) NCT00603382 · Phase 2 200 µg OD headache 7.9% (placebo 5.6%) nasopharyngitis 5% (placebo 7.5%) upper respiratory tract infection 3% (placebo 2.8%) NCT00603278 · Phase 2 100 µg OD headache 8.6% (placebo 5.6%) nasopharyngitis 8.6% (placebo 7.5%) diarrhoea 3.8% (placebo 0%) NCT00603278 · Phase 2 400 µg OD headache 9.1% (placebo 5.6%) cough 4% (placebo 0.9%) nasopharyngitis 4% (placebo 7.5%) NCT00603278 · Phase 2 300 µg OD headache 7.8% (placebo 5.6%) nasopharyngitis 6.8% (placebo 7.5%) back pain 2.9% (placebo 0%) NCT00603278 · Phase 2 200 µg OD dysphonia 4% (placebo 1%) oropharyngeal candidiasis 4% (placebo 1%) headache 3% (placebo 9.7%) NCT00603746 · Phase 2 800 µg OD headache 9.8% (placebo 9.7%) nasopharyngitis 6.9% (placebo 3.9%) oral candidiasis 6.9% (placebo 0%) NCT00603746 · Phase 2 600 µg OD headache 11.2% (placebo 9.7%) back pain 3.7% (placebo 1%) pharyngolaryngeal pain 2.8% (placebo 1%) NCT00603746 · Phase 2 400 µg OD headache 9.9% (placebo 9.7%) dysphonia 5% (placebo 1%) nasopharyngitis 5% (placebo 3.9%) NCT00603746 · Phase 2 100 µg OD nasopharyngitis 7.9% (placebo 5.2%) bronchitis 7% (placebo 6.1%) headache 6.1% (placebo 4.3%) NCT01159912 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 50 mcg upper respiratory tract infection 12.2% (placebo 13.8%) nasopharyngitis 9.7% (placebo 10.5%) rhinitis 6.7% (placebo 7.5%) NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 · registry result, not featured evidence 50 µg OD headache 14.5% (placebo 11.3%) nasopharyngitis 6.8% (placebo 5.2%) pharyngitis 6% (placebo 8.7%) NCT01436110 · Phase 3 · registry result, not featured evidence 50 µg OD nasopharyngitis 5.8% (placebo 4.1%) headache 5% (placebo 11.6%) pharyngitis 5% (placebo 5%) NCT01436071 · Phase 3 · registry result, not featured evidence 100/25 µg headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 · registry result, not featured evidence 200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 · registry result, not featured evidence 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 · registry result, not featured evidence 200/25 µg PM headache 16.1% (placebo 8.6%) back pain 3.6% (placebo 0%) sinus headache 3.6% (placebo 0%) NCT01086410 · Phase 3 · registry result, not featured evidence 100/25 µg PM headache 26.8% (placebo 8.6%) arthralgia 3.6% (placebo 0%) nasopharyngitis 3.6% (placebo 1.7%) NCT01086410 · Phase 3 · registry result, not featured evidence 100 µg AM headache 52.2% (placebo 36%) upper respiratory tract infection 26.1% (placebo 8%) nasopharyngitis 8.7% (placebo 4%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg PM headache 41.7% (placebo 36%) viral upper respiratory tract infection 20.8% (placebo 8%) dysmenorrhoea 8.3% (placebo 8%) NCT01808339 · Phase 2 · registry result, not featured evidence 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 100 µg headache 11.5% (placebo 0%) acute tonsillitis 3.8% (placebo 0%) cough 3.8% (placebo 0%) NCT01332292 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence 200 µg OD upper respiratory tract infection 5% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence 100 µg BID upper respiratory tract infection 4.9% (placebo 1.1%) NCT00766090 · Phase 2 · registry result, not featured evidence | 100/25 µg QDk upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence show 29 more results250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence 250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg headache 7% (placebo 3.9%) nasopharyngitis 7% (placebo 3.1%) upper respiratory tract infection 3.1% (placebo 4.7%) NCT02139644 · Phase 3 · registry result, not featured evidence 50 mcg nasopharyngitis 5.4% (placebo 3.1%) upper respiratory tract infection 5.4% (placebo 4.7%) headache 1.6% (placebo 3.9%) NCT02139644 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 · registry result, not featured evidence 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 · registry result, not featured evidence 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- eThe assessment timepoint is not available for both results.
- fTrial phases differ: Phase 3 versus Phase 2.
- gTrial phases differ: Phase 2 versus Phase 4.
- hAssessment timepoints differ: 4.14 weeks versus 52 weeks.
- iTrial phases differ: Phase 2 versus Phase 3.
- jPopulation comparability has not been reviewed for 41 of these studies.
- kPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone Furoate
show 3 more results
show 4 more results
show 5 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 18 further endpoints in the CSV export.
fluticasone propionate
show 1 more result
show 1 more result
show 1 more result
show 12 more results
show 4 more results
show 6 more results
+ 19 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone Furoate's landscape · fluticasone propionate's landscape